Specifically, they favor the tumor-promoting function of CD4+ T helper 2 lymphocytes over the tumor-protective T helper 1 response (21) and directly reduce the activation of CD8+ cytotoxic T cells and natural killer (NK) cells (22). The gene discussed is CD8A; the disease is neoplasm.